Why the study?
Response to CRT is heterogeneous and difficult to predict, driving interest in humoral biomarkers to stratify prognosis and identify responders.
Do predictive biomarkers help evaluate and predict response to cardiac resynchronization therapy in patients with heart failure?
Do predictive biomarkers help evaluate and predict response to cardiac resynchronization therapy in patients with heart failure?
While numerous biomarkers show promise in predicting response to cardiac resynchronization therapy, standardized, large-scale research is required before they can be routinely implemented in clinical practice.
Biomarkers should not yet guide CRT decisions in HF; leaves open the need for standardized large-scale validation studies.
Cardiac resynchronization therapy (CRT) was shown to greatly improve outcomes in specific patients with heart failure, low ejection fraction and wide QRS complex; however post-therapeutic response is heterogeneous and currently difficult to predict. There is an increasing interest in identifying humoral biomarkers which could help stratify prognosis, and better identify responders. The aim of this review was to provide an overview of recent data regarding the predictive value of biomarkers for evaluating response to CRT. A definitive conclusion cannot currently be drawn due to disparate results, varying methodologies, relatively small-scale studies and lack of consensus in defining CRT response. More extensive comparable research is paramount to facilitate progress in this field.
No takes yet. Share an insight, caveat, or question.
Pál et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: